15 results about "Anti-agents" patented technology

This invention provides compounds and methods of application that possess both broad-spectrum antifungal activity and plant-induced resistance, belonging to the field of agricultural technology. It addresses the problem that "traditional pure immune inducers must be applied before disease onset, making it difficult to meet the full-cycle control needs of disease prevention and treatment in the field." Compared to the previously developed PC1 and PC20, the two compounds of this invention, 2,4-dibromo-6-nitrophenol and 7-deazon-2'-deoxy-7-iodoadenosine, can both inhibit the growth of rice blast fungus and significantly improve rice resistance to rice blast through foliar spraying, meeting the full-cycle control needs of disease prevention and treatment in the field. Furthermore, these two compounds can directly inhibit the growth of various fungal pathogens such as peanut white mold, tomato gray mold, wheat scab, rice bakanae disease, rice false smut, mango malformation, and banana wilt.

Provided are methods and compositions for treatment of angiogenic disorders using anti-VEGF agents. The anti-VEGF agents comprise VEGF binding domains and have the ability to bind vitreous. Provided are exemplary embodiments of Fc-IgG fusion proteins with VEGF binding domains with strong heparin-binding characteristics, strong inhibition of VEGF mitogenic activity, and improved pharmacokinetics, namely longer half-lives of the anti-VEGF agents and consequently less frequent dosing.

Compositions and methods for making and using anti-TLR9 agents, for example, monoclonal antibodies, TLR9-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-TLR9 agents, and methods of making and using the same.

The present invention relates to the treatment of locally advanced or metastatic urothelial carcinoma (mUC) in a patient suffering from FGFR altered mUC and having disease progression during or after one or more prior treatments comprising a checkpoint inhibitor, in particular an anti-PD-(L) 1 agent, with erdatinib.

The invention relates to the technical field of chemical production, in particular to high-dispersion pearlescent color oil for plastics and a preparation method thereof.The pearlescent color oil comprises 50%-97.5% of grease, 2%-50% of pearlescent toner and 0-10% of auxiliaries, the grease is a compound system of carbomer and the like, and the auxiliaries comprise a dispersing agent, an antioxidant and an anti-UV agent; the preparation method comprises the steps of raw material pretreatment, mixing, quantitative dispersion and curing post-treatment, and the dispersion uniformity coefficient sigma is controlled to be smaller than or equal to 0.3 by determining the dispersion rotating speed and time. Through raw material optimization and process quantitative regulation and control, the color oil dispersion stability is improved, the color oil can adapt to PP, PET, ABS and other plastics, the appearance can be ensured to be uniform and free of flow lines under the condition of low addition amount, and the color oil has good weather resistance. The process is high in operability, does not need special equipment, is suitable for industrial mass production, and provides a high-quality solution for plastic decoration.

This invention provides a halogenated flame-retardant V-0 polyolefin masterbatch for silane self-crosslinking materials and its preparation method. It comprises the following raw material components in parts by weight: 20-23 parts LDPE; 53-56 parts brominated flame retardant; 17-19 parts antimony flame retardant; 0.8-1.2 parts coupling agent; 2-3 parts UV stabilizer; 1.4-1.6 parts lubricant; and 0.4-0.5 parts antioxidant. The LDPE has a melt flow index of 1.5-2.5 g / 10 min. The combined use of these components produces a synergistic effect: even with relatively low addition levels, the resulting silane self-crosslinking material achieves a UL 94V-0 flame retardant rating, effectively reducing costs.

This disclosure relates to a novel encapsulant film composition that provides anti-PID properties while maintaining good performance in terms of curing, adhesion, and volume resistivity. The composition comprises a) a polyolefin polymer, b) an organic peroxide, c) a silane adhesion promoter, and d) a crosslinking aid, and e) an anti-PID agent.

This invention discloses an antibacterial ABS composite molded mirror cabinet and its manufacturing process, comprising a main cabinet, side cabinets, and a splicing cabinet. Fixing holes are provided on the inner sides of the main cabinet, side cabinets, and splicing cabinets. The front ends of the main cabinet and splicing cabinets are hinged to provide a main mirror door structure, and the front ends of the side cabinets are hinged to provide a folding mirror door structure. The antibacterial ABS composite molded mirror cabinet and its manufacturing process utilize ABS substrate combined with a specific UV-resistant agent and chemically bonded silver ion antibacterial agent to achieve long-lasting anti-yellowing and durable antibacterial properties, solving the problem of mold growth in bathrooms. The cabinet body adopts an external splicing and internal one-piece molding design, balancing dimensional flexibility and leak-proof performance, and is enhanced with a 3D mirror door for a better user experience. Through multi-step process optimization, stable product quality and high production efficiency are ensured. Compared to wooden and ordinary plastic bathroom cabinets, it combines environmental friendliness and safety, superior mechanical properties, and no usage limitations, effectively solving the technical pain points of existing products.

This invention relates to the field of polymer composite materials technology, specifically providing a long-lasting antistatic ABS material and its manufacturing method. By weight, the material comprises the following raw materials: 100 parts ABS resin, 3-5 parts antistatic modifier, 1 part UV stabilizer, 1.5 parts polymer auxiliary conductive filler, and 0.2 parts antioxidant; wherein the antistatic modifier is a PEG-b-PS diblock copolymer. This invention achieves physical entanglement and permanent anchoring of molecular chains through the good compatibility between the PS segment of the PEG-b-PS block copolymer and the ABS matrix, while simultaneously utilizing the microphase separation of its PEG segments to construct hydrophilic conductive channels within the matrix; combined with the electronic conductive network of the auxiliary conductive filler, a dual "ion-electron" synergistic conductive mechanism is formed. This material possesses long-lasting, migration-resistant, abrasion-resistant, and aging-resistant antistatic properties, while causing minimal damage to the mechanical properties of the ABS matrix, maintaining high appearance, and achieving a surface resistivity of up to 10 Ω·cm. 9 -10 11 Ω / □, especially suitable for high-end cleanroom scenarios such as photomask protective film boxes.

Provided herein is a method for treating DLL3-expressing cancers using an anti-DLL3 antigen-binding protein administered subcutaneously. The anti-DLL3 antigen-binding protein comprises the amino acid sequence of SEQ ID NO: 13 and the amino acid sequence of SEQ ID NO: 22, and may be administered to a subject once every two weeks (Q2W), once every three weeks (Q3W), or once every four weeks (Q4W).

The present disclosure provides pharmaceutical compositions and methods thereof for the prevention or treatment of ocular neovascularization, such as AMD, in a subject, by administering to the subject a pharmaceutical composition comprising a rAAV vector having a nucleic acid sequence that encodes an anti-VEGF agent.

Compositions and methods for treating, inhibiting, preventing or reducing disorders and diseases in a subject by administering one or more anti-c-MYC agents are disclosed. In one aspect, a subject having a c-Myc-mediated disease, disorder or condition is treated with a compound of the disclosure including a compound selected from Formula (I), (I) wherein R is H, an in vivo cleavable linker or group, or a leaving group in aqueous solution and R1 and R2 are independently, H, alkyl, an aryl, a substituted alkyl, a substituted phenyl, a substituted aryl, or a combination thereof.

Treatment combinations are provided for FOLR1-binding immunoconjugates (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), platinum-based agents, and / or doxorubicin. Methods for administering said combinations to treat cancers, such as ovarian cancer, with increased clinical efficacy and / or reduced toxicity are also provided.

The disclosure relates to compositions and methods for treating DLL3-expressing cancers by administration of an anti-DLL3 antigen-binding agent (e.g., tarlatamab) to a subject once every four weeks (Q4W).

Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), platinum-based agents, and / or doxorubicin are provided. Methods of administering the combinations to treat cancer, e.g., ovarian cancer, with higher clinical efficacy and / or reduced toxicity are also provided.